New Eli Lilly Drug Retatrutide Brought Major Weight Loss in Trial
New Eli Lilly Drug Retatrutide Brought Major Weight Loss in Trial
The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.
Read the full article on NY Times Science
Truth Analysis
Analysis Summary:
The article appears mostly accurate, reporting on the trial results of Eli Lilly's retatrutide. The claim about significant weight loss is supported by multiple sources. There's a slight positive slant towards the drug's potential, but overall the reporting seems reasonably objective.
Detailed Analysis:
- Claim: The maker of Zepbound reported results from a study of retatrutide.
- Verification Source #5: Developed by Eli Lilly in Indianapolis, Indiana, it has shown even more promising results than tirzepatide and semaglutide, with trial
- Verification Source #2: In a phase 1b trial involving participants with type 2 diabetes, treatment with retatrutide resulted in a placebo-adjusted least-squares mean weight reduction
- Verification Source #4: The sponsor (Eli Lilly) designed and oversaw the conduct of the trial
- Assessment: Supported. Eli Lilly is the maker of Zepbound (tirzepatide) and is developing retatrutide. Multiple sources confirm Lilly's involvement in retatrutide trials.
- Claim: Retatrutide targets three hormones in the body.
- Verification Source #2: Triple–Hormone-Receptor Agonist Retatrutide for Obesity
- Assessment: Supported. Source 2 mentions retatrutide as a triple-hormone receptor agonist.
- Claim: Retatrutide led to much more weight loss than any approved drug.
- Verification Source #5: it has shown even more promising results than tirzepatide and semaglutide, with trial
- Assessment: Supported. Source 5 indicates that retatrutide has shown more promising results than existing drugs like tirzepatide (Zepbound) and semaglutide (Ozempic).
Supporting Evidence/Contradictions:
- Source 5: "Developed by Eli Lilly in Indianapolis, Indiana, it has shown even more promising results than tirzepatide and semaglutide, with trial"
- Source 2: "Triple–Hormone-Receptor Agonist Retatrutide for Obesity"